SCHEMBL5546124

SCHEMBL5546124

[CH2]c1ccccc1NCc1ccc(I)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
THRB P10828 1/20 0.44
ALOX12 P18054 1/20 0.44
HSD17B10 Q99714 3/20 0.43
HPGD P15428 3/20 0.40
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
APP P05067 2/20 0.39
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
GAA P10253 1/20 0.39
ADRA2C P18825 1/20 0.39
BACE1 P56817 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.36
EPAS1 Q99814 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538885 0.84 HSD17B10 (0.59) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5534733 0.81 KCNH3 (0.45) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5539503 0.81 MAPT (0.55) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5542578 0.81 HTT (0.52) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5544675 0.81 MAPT (0.44) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5541898 0.81 IDO1 (0.40) KDM4EHSD17B10HPGDTSHRHIF1A
SCHEMBL5544468 0.77 HIF1A (0.51) MAPTMEN1KMT2AL3MBTL1POLB
SCHEMBL5542641 0.77 EPHX2 (0.47) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5537509 0.77 NPC1 (0.50) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL5537807 0.76 PLK1 (0.55) KDM4EMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885MAPT 4117/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.